Revelation Biosciences Inc. Raises $9.6 Million Through Warrant Exercise

Revelation Biosciences Inc., a clinical-stage company specializing in inflammation rebalancing, has announced the immediate exercise of warrants, securing $9.6 million in gross proceeds. This involves the purchase of up to 4,355,000 shares of common stock at $2.20 each, originally issued in May 2025. The transaction's closure is anticipated around September 11, 2025, contingent on standard closing conditions.

Roth Capital Partners served as the financial advisor for this agreement. In return for the exercise, holders will receive new Class I warrants for up to 13,065,000 shares in a private placement, available for exercise post stockholder approval at $2.20 per share, with a five-year term.